Susquehanna International Group
RLMD icon

Susquehanna International Group’s Relmada Therapeutics RLMD Stock Holding History

Susquehanna International Group’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.04M Buy
1,011,572
+625,630
+162% +$2.96M ﹤0.01% 3650
2025
Q4 		$1.86M Buy
385,942
+247,518
+179% +$829K ﹤0.01% 5804
2025
Q3 		$278K Buy
138,424
+72,621
+110% +$69.7K ﹤0.01% 10294
2025
Q2 		$39.5K Buy
+65,803
New +$33.8K ﹤0.01% 12175
2024
Q4 		– Sell
-41,730
Closed -$102K – 13051
2024
Q3 		$135K Sell
41,730
-26,406
-39% -$85.5K ﹤0.01% 10833
2024
Q2 		$204K Buy
68,136
+41,777
+158% +$151K ﹤0.01% 10313
2024
Q1 		$123K Sell
26,359
-16,866
-39% -$81.3K ﹤0.01% 11081
2023
Q4 		$179K Buy
43,225
+13,354
+45% +$39.5K ﹤0.01% 10795
2023
Q3 		$89.6K Sell
29,871
-31,431
-51% -$93.4K ﹤0.01% 11009
2023
Q2 		$151K Sell
61,302
-16,812
-22% -$46.5K ﹤0.01% 10569
2023
Q1 		$177K Sell
78,114
-78,281
-50% -$270K ﹤0.01% 10747
2022
Q4 		$546K Buy
156,395
+117,377
+301% +$1.03M ﹤0.01% 7619
2022
Q3 		$1.44M Buy
+39,018
New +$1.08M ﹤0.01% 5696
2022
Q1 		– Sell
-23,255
Closed -$481K – 13829
2021
Q4 		$524K Sell
23,255
-11,575
-33% -$257K ﹤0.01% 9069
2021
Q3 		$913K Sell
34,830
-33,231
-49% -$889K ﹤0.01% 7812
2021
Q2 		$2.18M Buy
68,061
+6,683
+11% +$232K ﹤0.01% 5715
2021
Q1 		$2.16M Buy
61,378
+49,622
+422% +$1.74M ﹤0.01% 5736
2020
Q4 		$377K Buy
+11,756
New +$404K ﹤0.01% 8844
2020
Q2 		– Sell
-83,566
Closed -$3.53M – 10790
2020
Q1 		$2.85M Buy
83,566
+65,967
+375% +$2.66M ﹤0.01% 3378
2019
Q4 		$686K Buy
+17,599
New +$535K ﹤0.01% 6299

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Susquehanna International Group's RLMD Position: Q1 2026 in Review

Susquehanna International Group increased its Relmada Therapeutics (RLMD) stake by 162% in Q1 2026, buying an estimated $2.96M and bringing the position to 1,011,572 shares worth $7.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3650.

Susquehanna International Group first reported a position in RLMD in Q4 2019 and has held it in 20 quarters since. 103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Susquehanna International Group held 1,011,572 shares of Relmada Therapeutics worth $7.04M as of Q1 2026.
  • Susquehanna International Group bought 625,630 Relmada Therapeutics shares in Q1 2026, an estimated $2.96M.
  • Relmada Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3650 holding.
  • Susquehanna International Group first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 20 quarters since.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.